Potential

The novel bispecific T-cell engaging antibody has the potential to transform current hematopoietic stem cell transplantation practice into an immunologic precision-medicine approach.

Project Description

Phire is seeking to develop a novel bispecific T-cell engaging antibody in order to transform current hematopoietic stem cell transplantation (HSCT) practice into an immunologic precision-medicine approach. HSCT is a powerful intervention to cure life-threatening diseases of the blood and immune system, such as acute myeloid leukemia (AML).

For a successful transplant of blood stem cells, the patient’s diseased blood needs to be removed to make room for donor stem cells and to ensure engraftment and regeneration of the donor system in the patient’s body. Removing the patient’s own blood is the first step in a transplant and is called the “conditioning phase.” Today, this conditioning phase requires intensive chemotherapy and in some cases radiation – with severe side effects. These side effects prevent the majority of elderly and frail patients from receiving a transplant.

To establish the new therapeutic paradigm, Phire will initially focus on treating patients with AML. If successful, however, the bispecific antibody may be beneficial not only for the treatment of AML, but also for a variety of other hematological conditions, as it will revolutionize the way HSCT is performed. Our approach will therefore facilitate regenerative medicine on a larger scale. Not only AML patients, but every patient with a diseased blood system who might be cured by removing, replacing, or regenerating the hematopoietic system can benefit from our technology. Phire’s goal is to build a catalyst that makes regenerative medicine possible.

Contact

Bettina Steiner
Project Leader
bettina.steiner@wysszurich.ch

Bettina steiner portrait

Faculty Mentor

Markus G. Manz

Portrait manz 560

Faculty Mentor

Dario Neri

Portrait Phire mentor neri 560

Partners and Funding

  • VentureKick

Achievements

03/2022
Venture Kick winner stage 3

Phire wins Venture Kick's third stage of financial and entrepreneurial support. 

09/2021
Venture Kick Winner stage 2

Phire Therapeutics wins Venture Kick's second stage of financial and entrepreneurial support. Read more.

03/2021
Venture Kick Winner stage 1

Phire wins Venture Kick's first stage of financial and entrepreneurial support. 

02/2021
Wyss Zurich admission

Phire is accepted as full project at Wyss Zurich.

Core Team

Bettina steiner portrait

Bettina Steiner

Project Leader

Blank portrait

Renier Myburgh

Do you have a breakthrough project you want us to know about?

We urge you to contact the Wyss Zurich office to discuss your project and start the evaluation process.